Health

Takeda, Merck & Co, Ipsen and Merck Group all scored exits as the immuno-oncology drug developer floated at the bottom of its IPO range.

Blue Venture Fund and CVS Health Ventures helped the telemedicine system developer raise funding which will boost its expansion into new markets and expand its treatment offering.

Leverage Health Solution, Cigna Ventures and Leaps by Bayer helped the skin condition treatment developer hike its total funding to approximately $67m.

N26, which counts corporates among its previous backers, raised a sizeable round at a $9bn valuation. This round comes to underscore the growth in valuations we have been seeing in the fintech space.

Osage University Partners has helped the UT Southwestern precision medicine spinout close a round which will be used to advance and expand its pipeline of respiratory disease drug candidates.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Pfizer and Sanofi helped the precision medicine developer close a series B round which will be used to advance and expand its pipeline of respiratory disease drug candidates.

Sumitomo Mitsui’s DS Asset Management subsidiary backed the neurological and metabolic disorder drug developer in a round that will support clinical trials.

Eli Lilly, WuXi AppTec and Schrodinger were among the investors in the cardiovascular, pulmonary and metabolic disorder drug developer's latest round.

Digital health drives healthcare investments to record heights

Battery swapping service Sun Mobility closed $50m in funding from Vitol while Sinopharm-backed drug developer Sinotau raised the same amount in a series D-plus round.